Through this approach, BRCA1 and BRCA2 mutations have been identified as targetable genetic mutations in metastatic BC; targeted therapies (usage of PARP inhibitors, such as olaparib) have indeed been shown to be effective in treating patients with BRCA-positive BCs [111]. This evidence concerns the gene BRCA1 and breast cancer.